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Abstract
Background: Youth in southern Africa, particularly adolescent girls and young women, are a key population for HIV
prevention interventions. Untreated genital tract infections (GTIs) increase both HIV transmission and acquisition
risks. South African GTI treatment guidelines employ syndromic management, which relies on individuals to report
GTI signs and symptoms. Syndromic management may, however, underestimate cases, particularly among youth.
We compared genital tract infection (GTI) prevalence by symptom-based and laboratory assessment among
sexually-experienced youth in South Africa, overall and stratified by sex.
Methods: Interviewer-administered surveys assessed socio-demographics, behaviors, and GTI symptoms among
352 youth (16-24 yrs., HIV-negative or unknown HIV status at enrollment) enrolled in community-based cohorts in
Durban and Soweto (2014–2016). Laboratory tests assessed HIV, Chlamydia trachomatis (CT), Neisseria gonorrhoeae
(NG), Mycoplasma genitalium (MG), Trichomonas vaginalis (TV) infections and, among females, bacterial vaginosis (BV)
and Candida species. Youth with genital ulcers were tested for HSV-2 and syphilis. We assessed sensitivity (and
specificity) of symptom-based reporting in identifying laboratory-confirmed GTIs.
Results: At baseline, 16.2% of females (32/198) and < 1% (1/154) of males reported ≥1 GTI symptom. However,
laboratory tests identified ≥1 GTI in 70.2% and 10.4%, respectively. Female CT prevalence was 18.2%, NG 7.1%,
MG 9.6%, TV 8.1%, and 5.1% were newly diagnosed with HIV. BV prevalence was 53.0% and candidiasis 9.6%. One
female case of herpes was identified (0 syphilis). Male CT prevalence was 7.8%, NG 1.3%, MG 3.3%, TV < 1%, and
2.0% were newly diagnosed with HIV. Overall, 77.8% of females and 100% of males with laboratory-diagnosed GTIs
reported no symptoms or were asymptomatic. Sensitivity (and specificity) of symptom-based reporting was 14%
(97%) among females and 0% (99%) among males.
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Conclusion: A high prevalence of asymptomatic GTIs and very poor sensitivity of symptom-based reporting
undermines the applicability of syndromic GTI management, thus compromising GTI control and HIV prevention
efforts among youth. Syndromic GTI management does not meet the sexual health needs of young people. Policy
changes incorporating innovations in GTI diagnostic testing are needed to reduce GTIs and HIV-associated risks
among youth.
Keywords: Adolescents and young adults, Youth, Women, Sexually transmitted infections, Genital tract infections,
HIV prevention, Screening, Syndromic management, Performance analysis, South Africa
Background
Adolescents and young adults (aged 15–24 years) account
for one-third of incident adult HIV infections in South
Africa. Girls and young women are particularly at risk,
with nearly 2000 young women acquiring HIV every week
[1, 2]. Accordingly, reducing HIV risk among youth re-
mains a pressing global public health priority [3].
Untreated genital tract infections (GTIs) increase risk
of HIV acquisition and transmission through several
organism-specific pathways [4, 5]. Untreated HIV can
also increase GTI severity and duration through im-
mune suppression pathways. For women, untreated
GTIs are a significant cause of reproductive morbidity,
including pelvic inflammatory disease, tubal factor in-
fertility, adverse birth outcomes, and infertility [6].
The success of GTI control programs is predicated on
timely and effective diagnosis and treatment [7]. South
African GTI treatment guidelines employ syndromic man-
agement [8], consistent with WHO recommendations [9].
Syndromic management is based on the identification of
syndromes (i.e., consistent groups of symptoms and clin-
ical signs) associated with infection by a defined pathogen,
followed by syndromic treatment for the most common
causative GTI organisms.
While syndromic GTI management can be used to treat
and manage symptomatic GTIs at the primary healthcare
level without the need for laboratory facilities or diagnos-
tic tests, such an approach can underestimate GTI cases,
particularly among women for whom an estimated 50–
75% of those with a GTI are asymptomatic [10, 11]. Few
studies from high HIV-burden settings have examined
GTI prevalence or diagnostic performance of syndromic
management among adolescents and young adults [11].
This is concerning given the dual burdens and synergies
between HIV and GTIs among youth and the potential for
long-term sequelae. There are also concerns about the
ability of syndromic treatment to differentiate between the
etiologies of the disease, leading to the potential for
over-prescription of antibiotics and attendant risks of anti-
microbial resistance [5].
This analysis measured and compared GTI prevalence
by syndromic-based and laboratory assessment among
sexually-experienced South African adolescents and young
adults, stratified by sex. We assessed the performance of
syndromic GTI management compared with the ‘gold
standard’ of laboratory diagnosis (including measurement
of sensitivity, specificity, positive predictive value [PPV],
and negative predictive value [NPV]. In pursuing these ob-
jectives, we seek to inform GTI control programs for
youth in the context of emerging biomedical HIV preven-
tion efforts.
Methods
Study design and participants
We used baseline data from adolescents and young adults
(females and males) enrolled in the AYAZAZI study, a
youth-centered, dual-site, community-based, prospective
cohort study focused on understanding linked patterns of
socio-behavioural and biomedical HIV risk among youth
in South Africa [12].
AYAZAZI study inclusion criteria included being 16–
24 years of age, residing in Soweto or Durban, self-reporting
an HIV-negative or unknown HIV status, and being willing
and able to provide voluntary written informed consent. Ex-
clusion criteria included current participation in another
clinical or observational HIV prevention study. The Soweto
cohort was based at the Perinatal HIV Research Unit
(PHRU) located at Chris Hani Baragwanath Hospital. The
Durban cohort was based at the Commercial City research
site led by MatCH Research Unit (MRU).
We used posters, pamphlets, word-of-mouth, and
in-person community outreach to recruit 425 participants
(253 females, 172 males) across both sites. In Soweto, par-
ticipants were also recruited through the PHRU’s HIV
testing and counselling clinic while in Durban, partici-
pants were also recruited through a public sector repro-
ductive health clinic at Commercial City. Enrolment
occurred between November 2014 and April 2015 in So-
weto and between September 2015 and April 2016 in
Durban.
Study procedures
Participants completed a structured questionnaire (sup-
ported by DataFAX™ software) at enrolment, administered
in-person by youth interviewers. The questionnaire
assessed demographic characteristics, social determinants
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of health, healthcare-seeking behaviours, sexual behav-
iors, pregnancy history, substance use, experiences of
violence, and self-perceived HIV risk. Questionnaires
were conducted in English, isiZulu, or Sesotho, as per
participant preference. Participants received a 150 ZAR
(~$12 USD) reimbursement per visit to compensate for
transportation costs and time.
Presence of GTI symptoms was assessed via a nurse-ad-
ministered questionnaire. All participants underwent a
nurse-led physical examination (including genital examin-
ation for presence of a genital ulcer), consistent with
standard treatment guidelines [8].
Urine (males) and nurse-collected vaginal swab (fe-
males) specimens were collected and transported daily to
the National Institute for Communicable Diseases in Jo-
hannesburg (for the Soweto site) and the Global Clinical
and Viral Laboratory (for the Durban site) for analysis.
Using multiplex nucleic acid amplification test (NAAT)
methods, all participants were tested for Chlamydia tra-
chomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma
genitalium (MG), and Trichomonas vaginalis (TV). All fe-
males were tested for the presence of bacterial vaginosis
(BV) and Candida species (CA) using Gram-stain tech-
niques. Vaginal microbiota specimens were evaluated
using Nugent criteria, which differentiate between BV
(scores 7–10), intermediate microbiota (scores 4–6), and
normal microbiota (scores 0–3) [13]. Participants with ac-
tive genital ulcers identified during physical exams were
tested for herpes simplex virus type 2 (HSV-2),Treponema
pallidum, Haemophilus ducreyi and C.trachomatis serovar
L1-L3 via multiplex PCR using the Roche LightCycler.
AYAZAZI clinical staff offered counselling and treatment
(either onsite or via referral to a local clinic) to partici-
pants immediately following a syndromic diagnosis or
after receipt of positive GTI laboratory results. Recent
data demonstrating increased inflammation and thus HIV
acquisition risk among women with asymptomatic BV in-
formed study procedures to include asymptomatic BV
cases as requiring treatment, after confirmation using
Nugent criteria [14].
For female participants, research nurses performed rapid
pregnancy testing using the QuickVue One-Step HCG
urine test (Quidel Corporation, San Diego, CA, USA).
Vaginal swabs were deferred for a week for menstruating
women, and deferred until pregnancy resolution.
All participants were tested for HIV using the Abon™
HIV 1/2/0 Tri-Line HIV RDT test (Abon Biopharm Co.
Ltd., Hangzhou, China) with confirmatory testing using
the First Response™ HIV-1-2.0 Rapid Whole Blood Test
kit (Premier Medical Corporation Private Ltd., Gujarat,
India). Those who tested negative on the first rapid test
were considered HIV-negative and offered standard
HIV prevention counselling. Individuals who tested
positive using both the rapid HIV tests were considered
HIV-positive, counselled, and referred to a local clinic for
further assessment, including CD4 testing, and counsel-
ling on initiation of antiretroviral therapy (ART). CD4 T
cells were enumerated from whole blood using
Tru-Count technology and analysed on a FACSCalibur
flow cytometer (Becton Dickinson). If one rapid test
was positive and the other negative, offsite confirmation
was conducted using 3rd generation (i.e., antibody only)
ELISA tests (MICROLISA HIV test, J.Mitra & Co. Ltd.,
New Delhi, India [Soweto]; Vironostika HIV Uni-Form II
Plus O test, Biomerieux, Marcy L’Etoile, France [Durban]).
Measures
We measured the prevalence and types of nine
self-reported GTI symptoms (for both female and male
participants) and associated seven syndromes, stratified
by sex [8, 9] (Additional file 1: Table S1).
We measured the prevalence of laboratory-confirmed
GTIs, stratified by sex. Ulcerative STIs were analysed
separately from non-ulcerative STIs, as only the etio-
logical distribution of ulcerative STIs could be reported
as opposed to prevalence. We measured the prevalence
of (a) each GTI screened, (b) ≥1 GTI, (c) co-infection
with ≥2 non-ulcerative STIs, (d) co-infection with ≥1
non-ulcerative STI and BV, and (e) newly-diagnosed HIV.
Statistical analysis
Of 425 participants enrolled in AYAZAZI, this GTI ana-
lysis was restricted to sexually-experienced (excluded n =
64) and non-pregnant (excluded n = 9) youth, yielding a
final analytic sample of 352 (82.4% of the total cohort).
Descriptive statistics (median [IQR] for continuous
variables and n [%] for categorical variables) were used
to characterize baseline distributions of study variables,
stratified by natal sex (female or male). Baseline differ-
ences between females and males were compared using
Wilcoxon rank sum test for continuous variables and
Pearson χ2 or Fisher’s exact test for categorical variables.
Descriptive statistics were used to characterize (1) distri-
bution of GTI symptoms and syndromes by sex and by
study site; and (2) distribution of laboratory-confirmed
infections by sex and study site.
For sensitivity, specificity, PPV, and NPV calculations
[15], the gold-standard was a positive laboratory test re-
sult for any aetiological agent of the syndrome, defined
as follows [8, 9]: Vaginal Discharge Syndrome (VDS):
NG, CT, MG (cervical infections), or TV, BV, or CA (va-
ginal infections); Lower Abdominal Pain (LAP): NG, CT,
or, MG; Male Urethritis Syndrome (MUS): NG, CT, MG,
or TV; and Scrotal Swelling (SSW): NG or CT.
Sensitivity analysis of VDS was stratified by cervical,
vaginal, and BV as the causative agent to compare per-
formance statistics for each infection type and considering
that the high BV prevalence could augment performance
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statistics relative to other VDS-associated organisms.
Performance analysis of Genital Ulcer Disease (GUD) was
not possible as only those with genital ulcers (n = 3) were
tested for ulcerative-STIs. Data were analyzed with SAS
version 9.1.
All participants aged 18–24 years provided voluntary
informed consent at enrollment. For participants aged
16–17 years, parents/legal guardians provided voluntary
written informed consent and the participant provided
voluntary written informed assent. Ethical approval was
provided by the Research Ethics Boards of Simon Fraser
University (Canada), the University of the Witwatersrand




Of 352 youth included in this analysis, 56% were female,
17.1% were less than 18 years old, 6.8% identified as
LGBTQ (lesbian, gay, bisexual, transgender, and queer),
66.1% were currently in school and 25.9% reported high
food insecurity. All participants identified as cis gender.
Over one-quarter reported living in informal housing
(27.6%) or having a personal monthly income < 400 ZAR
(~$30 USD) (26.4%), with significant differences by sex
(p < 0.05).
We also observed several differences in sexual and re-
productive experiences by sex. While 55.6% of youth
self-perceived as having no or low risk of HIV, 20.7% of
females and 45.5% of males reported ≥2 sexual partners
in the past 6 months (p < 0.001), and 80.6% of females
and 51.3% of males reported inconsistent condom use
(p < 0.001). A higher proportion of males than females
reported ever having engaged (i.e., provided or received)
in transactional sex (22.9% and 7.2%; respectively), while a
higher proportion of females than males reported an
age-disparate sex partner (i.e., ≥ 5 years older or younger)
(34.9% and 12.4%; respectively) (Table 1).
GTI symptoms and associated syndromes
Among females, 16.2% (32/198) reported ≥1 GTI symptom.
The most commonly reported symptoms were vaginal
discharge (7.1%) and vaginal itching or irritation (4.5%). By
syndrome, 10.6% of females reported symptoms of
VDS, 6.6% of LAP, and 2.0% of GUD. Among males,
0.7% (1/154) reported symptoms compatible with MUS
(urethral discharge); no other STI syndromes were de-
scribed in males (Table 2).
Laboratory-confirmed prevalence of GTIs
Laboratory tests identified ≥1 GTI in 44.0% of study par-
ticipants, including 70.2% of females and 10.4% of males
(p < 0.001) (Table 3).
Among female participants, over one-third (34.8%;
n = 69/198) were infected with at least one non-ulcerative
STI, including 18.2% with CT, 7.1% with NG, 9.6% with
MG, and 8.1% with TV. Of those infected with ≥1 one
non-ulcerative STI (n = 69), one-fifth (20.3%; n = 14) were
co-infected with other STI pathogens while nearly
three-quarters (72.5%; n = 50) were co-infected with a
GTI. By site, the prevalence of non-ulcerative STIs was
higher among females in Soweto compared with Durban
(44.1% and 25.0% respectively, p = 0.008). Of two young
women with genital ulcers, one case of herpes was con-
firmed and there were no cases of laboratory-proven syph-
ilis. Just over half (53.0%) of all females tested positive for
BV, with a further 11 females having intermediate flora
(5.6%). Prevalence of CA was 9.6%. One-quarter (25.3%)
of females were co-infected with a non-ulcerative STI and
BV or CA. Ten female participants (5.1%) were newly di-
agnosed with HIV (median CD4 = 301 cells/mm3 [IQR:
197–392], with a significantly higher baseline HIV preva-
lence in Durban than Soweto (9.4% and 1.0%, respectively;
p = 0.008). Overall, 90.0% (9/10) of HIV-positive females
were co-infected with BV, while none had an STI.
Among male participants, one-tenth (10.4%; n = 16/154)
were infected with at least one non-ulcerative STI, includ-
ing 7.8% with CT, 1.3% with NG, 3.3% with MG, and 0.7%
with TV. Of those infected with an MUS-associated STI,
one-quarter (25.0%) were co-infected. No STI pathogen
was detected in the single male participant with genital ul-
cers. Three male participants (2.0%) were newly diagnosed
with HIV (median CD4 = 102 cells/mm3 IQR: 85–119),
with a non-statistically significant higher HIV prevalence
in Durban compared to Soweto (2.4% and 1.4%, respect-
ively, p = 1.00). No HIV-positive males were co-infected
with an STI.
Sensitivity analysis
Overall, only 22.2% of females and 0% of males with a
confirmed GTI reported at least one GTI symptom. In
other words, 77.8% of females and 100% of males with
laboratory-diagnosed GTIs reported no accompanying
symptoms or were asymptomatic (Table 4).
Females
Sensitivity analyses revealed that VDS symptomology
poorly indicated infection with associated pathological
organisms (i.e., NG, CT, MG, TV, BV, or CA). Overall,
19/21 reporting VDS symptoms were infected with a
VDS-associated GTI; however, of 139 females with
laboratory-confirmed infections with a VDS-associated
GTI, just 19 reported symptoms (sensitivity 13.7%, spe-
cificity 96.6%, PPV 90.5%, NPV 32.2%). When restricted
to cervical STIs as the causative agents of VDS, sensi-
tivity, specificity and PPV all decreased to 11.7%, 89.9%,
and 33.3% (respectively), while NPV increased to 70.1%.
Kaida et al. BMC Infectious Diseases  (2018) 18:499 Page 4 of 11
Table 1 Baseline characteristics of sexually-experienced and non-pregnant youth (aged 16–24 years) enrolled in the AYAZAZI study













Study Site 352 0.314
Soweto 173 (49.2) 102 (51.5) 71 (46.1)
Durban 179 (50.8) 96 (48.5) 83 (53.9)
Age category, years 352 0.734
16 to 17 60 (17.1) 31 (15.7) 29 (18.8)
18 to 20 187 (53.1) 107 (54.0) 80 (52.0)
21 to 24 105 (29.8) 60 (30.3) 45 (29.2)
Sexual orientation 351 0.533
Heterosexual 327 (93.2) 183 (92.4) 144 (94.1)
LGBTQa 24 (6.8) 15 (7.6) 9 (5.9)
Currently in school 351 0.615
Yes 232 (66.1) 128 (65.0) 104 (67.5)
No 119 (33.9) 69 (35.0) 50 (32.5)
Food insecurityb 347 0.989
Low 257 (74.1) 143 (74.1) 114 (74.0)
High 90 (25.9) 50 (25.9) 40 (26.0)
Housing 352 0.006
Formal 255 (72.4) 132 (66.7) 123 (79.9)
Informalc 97 (27.6) 66 (33.3) 31 (20.1)
Monthly personal incomed 352 0.008
< 400 ZAR 93 (26.4) 43 (21.7) 50 (32.5)
401–1600 ZAR 174 (49.4) 112 (56.6) 62 (40.3)
1601+ ZAR 85 (24.2) 43 (21.7) 42 (27.3)
Sexual history and socio-structural variables
Self-perceived HIV risk 347 0.940
None/low risk 193 (55.6) 107 (55.4) 86 (55.8)
Medium/high risk 154 (44.4) 86 (44.6) 68 (44.2)
≥2 Sexual partners in P6me 352 < 0.001
Yes 111 (31.5) 41 (20.7) 70 (45.5)
No 241 (68.5) 157 (79.3) 84 (54.5)
Condom use in P6m 343 < 0.001
Consistent (“always”) 111 (32.4) 37 (19.4) 74 (48.7)
Inconsistent (“sometimes”/“never”) 232 (67.6) 154 (80.6) 78 (51.3)
Age-disparate sex partner in P6mf 340 < 0.001
Yes 85 (25.0) 68 (34.9) 18 (12.4)
No 255 (75.0) 127 (65.1) 127 (87.6)
Ever had transactional sexg 347 < 0.001
Yes 49 (14.1) 14 (7.2) 35 (22.9)
No 298 (85.9) 180 (92.8) 118 (77.1)
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When restricted to vaginal STIs as the causative agents
of VDS or only BV, performance measures were also
poor (for BV: sensitivity 13.3%, specificity 92.5, PPV
66.7%, NPV 48.6%).
Similarly, LAP symptomology poorly indicated infection
with associated pathogens (i.e., NG, CT, MG), with both
poor sensitivity and poor PPV. Overall, only 4/13 females
reporting LAP symptoms were infected with a LAP-
associated GTI; while of 57 females with confirmed infection
with a LAP-associated GTI, just 4 reported symptoms
(sensitivity 7.0%, specificity 93.4%, PPV 30.8%, NPV 70.6%).
Males
No MUS-associated pathogen (i.e., NG, CT, MG, and/or
TV) was detected in the one male reporting urethral dis-
charge. Of 16 males truly infected with a MUS-associated
STI, none reported symptoms (sensitivity 0%, specificity
99.3%, PPV 0%, NPV 89.5%).
Discussion
GTIs, including asymptomatic infections, induce genital
tract inflammation among young women, increasing
HIV acquisition risk [14]. We found a high and fre-
quently asymptomatic burden of GTI infection among
South African youth, with significant differences by sex.
While only 16% of young women and < 1% of young
men reported GTI-related symptoms, laboratory tests
identified at least one GTI in 70% of females and 10% of
males. Syndromic GTI management revealed very poor
sensitivity. The high burden of asymptomatic GTIs con-
tributes to a silent GTI epidemic in youth, which re-
quires additional attention, innovations, and resources to
control. We strongly recommend policy changes to re-
place syndromic management with innovative public
health approaches, inclusive of widespread diagnostic
testing to reduce GTI burden and HIV-associated risks
among youth.
The high GTI prevalence observed here is particularly
notable, given that participants are young (16–24 years
of age), primarily recruited from community settings, and
were not enrolled due to high GTI risk. Nonetheless, over
one-third of young women had at least one non-ulcerative
STI and half had laboratory-detected BV. The prevalence
of each non-ulcerative STI (CT: 18.2%; NG: 7.1%; MG:
9.6%; TV: 8.1%) was higher or similar to the prevalence
observed among older women (18–40 years) presenting
for STI care in Durban (CT: 18.4%; NG: 5.2%; MG: not
assessed; TV: 3.0%) [16], high HIV-risk women enrolling
in the CAPRISA 002 Acute HIV Infection study in
Durban (overall STI prevalence = 25.3%; CT: 4.2%; NG:
5.4%; MG: 1.2%; TV: 20.3%) [17], women enrolled in three
large clinical trials in Durban (STI prevalence = 13%) [18],
“high HIV risk” Tanzanian women (CT: 12%; NG: 4%;
MG: not assessed; TV: 19%) [19], and women attending
antenatal care in Kenya (CT: 14.9%; NG: 1.0%; MG: not
assessed; TV: 7.4%) [20]. The exception to this pattern
was TV, which was lower in female youth in our study
relative to older women in both the Tanzanian and South
African studies. Such patterns are consistent with known
biological reasons for increases in TV prevalence with age
(i.e., protozoal accumulation over time). The high BV
prevalence (53.0%) mirrors levels reported in other South
African studies [4, 17, 18, 21, 22].
Fewer (10%) young men in our study had a laboratory-
confirmed non-ulcerative STI compared to women. STI
prevalence among men was driven largely by CT (7.8%).
Our findings are consistent with the limited available data
regarding STI prevalence for young and older heterosexual
men in South Africa [23, 24].
We observed a 3.7% prevalence of HIV sero-positivity at
baseline, despite study eligibility criteria aimed at enrolling
HIV-negative participants. Moreover, low median CD4
cell counts at HIV diagnosis signal advanced HIV disease
progression. HIV prevalence was higher among Durban
Table 1 Baseline characteristics of sexually-experienced and non-pregnant youth (aged 16–24 years) enrolled in the AYAZAZI study












Ever been/made pregnant 352 < 0.001
Yes 118 (33.5) 93 (47.0) 25 (16.2)
No 234 (66.5) 105 (53.0) 129 (83.8)
Ever experienced physical/sexual violence 347 0.001
Yes 59 (17.0) 45 (23.3) 14 (9.1)
No 288 (83.0) 148 (76.7) 140 (90.9)
Notes: a LGBTQ refers to individuals who identify their sexual orientation as Lesbian, Gay, Bisexual, Transgender, or Queer; b Food insecurity was defined as high if
the participant or a household member had ever slept hungry, had no food to eat because of lack of money, or ever went a day and night without eating;
c Informal housing includes RDP housing (government subsidized housing), shacks, or hostels; d ZAR = South African Rand, with 400 ZAR = $25 USD and 1601 ZAR
= $100 USD using the May 30, 2016 currency exchange rate of 1 ZAR = 0.063 USD; e P6m refers to the 6 months prior to interview; f Sexual partner is ≥5 years
older or younger than participant; g Transactional sex was classified as ever having sex with someone in exchange for something (given or received)
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participants compared to Soweto, consistent with findings
from surveillance data [1]. Given the known synergistic re-
lationship between HIV and STI co-infection, the higher
prevalence of non-ulcerative STIs but lower prevalence of
HIV in Soweto is notable.
Consistent with previous reports, syndromic manage-
ment was unable to detect the majority of GTIs due to
their asymptomatic nature [17, 25]. Without laboratory
testing, approximately 80% of prevalent GTIs among
young women and 100% among young men in our study
would have remained untreated. Poor sexual health know-
ledge and a lack of familiarity with GTI symptoms among
youth may have exacerbated under-reporting of symptoms
[26–28]. Both VDS and LAP had poor sensitivity (13.7%
and 7.0% respectively). This is a well-documented limita-
tion to the VDS algorithm, especially for cervical infection
Table 2 Sex-stratified prevalence of genital tract infection (GTI) symptoms and associated syndromes reported by sexually
experienced, non-pregnant South African youth (aged 16–24 years) enrolled in the AYAZAZI study, overall and by site (n = 352)
Durban Soweto Whole cohort
Females n = 96
Males n = 83
Females n = 102
Males n = 71
Females n = 198
Males n = 154
n (%) n (%) n (%)
Female-specific symptoms:
Vaginal discharge 6 (6.3) 8 (7.8) 14 (7.1)
Dysuria 0 (0) 4 (3.9) 4 (2.0)
Vaginal Itching or irritation 4 (4.2) 5 (4.9) 9 (4.5)
Vaginal redness or swelling 0 (0) 1 (1.0) 1 (0.5)
Lower abdominal or groin pain (with/without vaginal discharge) 1 (1.0) 4 (3.9) 5 (2.5)
Dyspareunia 0 (0) 2 (2.0) 2 (1.0)
Post-coital bleeding or metrorrhagia 2 (2.1) 4 (3.9) 6 (3.0)
Vaginal sores or skin changes 3 (3.1) 1 (1.0) 4 (2.0)
None of the above 82 (85.4) 82 (80.4) 164 (82.8)
≥ 1 symptom 12 (12.5) 20 (19.6) 32 (16.2)
Female-specific syndromes:
Vaginal Discharge Syndrome (VDS) 8 (8.3) 13 (12.8) 21 (10.6)
Lower Abdominal Pain (LAP) 3 (3.1) 10 (9.8) 13 (6.6)
Genital Ulcer Disease (GUD) 3 (3.1) 1 (1.0) 4 (2.0)
Male-specific symptoms:
Sores or skin changes around penis or scrotum 0 (0) 0 (0) 0 (0)
Urethral discharge 0 (0) 1 (1.4) 1 (0.7)
Dysuria 0 (0) 0 (0) 0 (0)
Pain, swelling or redness of scrotum 0 (0) 0 (0) 0 (0)
Pain in testes 0 (0) 0 (0) 0 (0)
Soreness or itching around foreskin (if uncircumcised) 0 (0) 0 (0) 0 (0)
Hot tender swelling with redness 0 (0) 0 (0) 0 (0)
None of the above 83 (100.0) 70 (98.6) 153 (99.4)
≥ 1 symptom 0 (0) 1 (1.4) 1 (0.7)
Male-specific syndromes:
Genital Ulcer Disease (GUD) 0 (0) 0 (0) 0 (0)
Male Urethritis (MUS) 0 (0) 1 (1.4) 1 (0.7)
Scrotal Swelling (SSW) 0 (0) 0 (0) 0 (0)
Balanitis 0 (0) 0 (0) 0 (0)
Bubo 0 (0) 0 (0) 0 (0)
Notes: GTI symptoms and syndromes are classified based on WHO and South African STI management guidelines (WHO 2004, South African Department of Health 2015)
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[17, 21, 29]. VDS had a high PPV (90.5%) indicating that
most women who reported VDS-related symptoms did
have a laboratory-confirmed GTI and would have been
appropriately treated under syndromic management. That
is, syndromic management performed appropriately in its
role of detecting and managing symptomatic GTIs. How-
ever, the PPV for LAP was poor (30.8%) highlighting that
a majority of young women who reported LAP-associated
symptoms did not have a laboratory-confirmed GTI and
may have been inappropriately treated under syndromic
management guidelines. Insufficient symptomatic infec-
tion in young men in our study precluded robust sensitiv-
ity analyses of syndromic management; no men with an
STI reported symptoms and no men who reported symp-
toms had an STI.
There are important advantages to syndromic man-
agement on a national scale; the primary being cost,
and a second being that it requires a single visit, de-
creasing the likelihood of treatment loss-to-follow-up
at a second visit, typically required with diagnostic
testing [9]. These advantages must be considered
against the performance of syndromic approaches for
high-priority populations. Our findings suggest that
in South Africa, both male and female youth have a
high burden of undetected GTIs. Reliance on a syn-
dromic management approach will continue to yield
low detection of prevalent GTIs and thus poor GTI
control.
Our findings suggest a need to evolve sexual health
services to benefit youth. Although a test-and-treat ap-
proach to GTIs has historically posed financial and logis-
tical challenges, recent innovations in affordable real-time
STI testing, such as point-of-care (POC) diagnostics, war-
rant further investigation for wide-scale implementation
Table 3 Sex-stratified prevalence of laboratory-confirmed genital tract infections (GTIs) among sexually experienced, non-pregnant
South African youth (aged 16–24 years) enrolled in the AYAZAZI study, overall and by study site (n = 352)
Laboratory-confirmed
infections



















≥ 1 GTI (excluding HIV) 66 (68.8) 10 (12.0) 76 (42.5) 73 (71.6) 6 (8.5) 79 (45.7) 139 (70.2)* 16 (10.4)* 155 (44.0)
Non-ulcerative STIs
C. trachomatis (CT) 14 (14.6) 7 (8.4) 21 (11.7) 22 (21.6) 5 (7.0) 27 (15.6) 36 (18.2)* 12 (7.8)* 48 (13.6)
N. gonorrhoeae (NG) 5 (5.2) 2 (2.4) 7 (3.9) 9 (8.8) 0 (0) 9 (5.2) 14 (7.1)* 2 (1.3)* 16 (4.6)
M. genitalium (MG) 5 (5.2) 3 (3.6) 8 (4.5) 14 (13.7) 2 (2.8) 16 (9.3) 19 (9.6)* 5 (3.3)* 24 (6.8)
T. vaginalis (TV) 3 (3.1) 0 (0) 3 (1.7) 13 (12.8) 1 (1.4) 14 (8.1) 16 (8.1)* 1 (0.7)* 17 (4.8)
≥ 1 of CT/NG/MG 22 (22.9) 10 (12.0) 32 (17.9) 38 (37.3) 5 (7.0) 43 (24.9) 60 (30.3)* 15 (9.7)* 75 (21.3)
≥ 1 non-ulcerative STI 24 (25.0) 10 (12.0) 34 (19.0) 45 (44.1) 6 (8.5) 51 (29.5) 69 (34.8)* 16 (10.4)* 85 (24.1)
Female-only GTIs
Bacterial Vaginosis (BV) 52 (54.2) 53 (52.0) 105 (53.0)
C. albicans (CA) 7 (7.3) 12 (11.8) 19 (9.6)
Co-infection
≥ 2 non-ulcerative STIs 3 (3.1) 2 (2.4) 5 (2.8) 11 (10.8) 2 (2.8) 13 (7.5) 14 (7.0)* 4 (2.6)* 18 (5.0)
≥ 1 non-ulcerative STI
& ≥1 GTI
16 (16.7) 34 (33.3) 50 (25.3)
Among those with ≥ 1 non-ulcerative STI
≥ 2 non-ulcerative STIs 3 (12.5) 2 (20.0) 5 (14.7) 11 (24.4) 2 (33.3) 13 (25.5) 14 (20.3) 4 (25.0) 18 (21.2)
≥ 1 non-ulcerative STI
& ≥1 GTI
16 (66.7) 34 (75.6) 50 (72.5)
Ulcerative STIs (among
those with genital ulcers)a
n = 1 n = 0 n = 1 n = 1 n = 1 n = 2 n = 2 n = 1 n = 3
HSV-2 1 (100.0) 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0) 1 (50.0) 0 (0) 1 (33.3)
T. pallidum 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
H. ducreyi 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
LGV 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
HIVb 9 (9.4) 2 (2.4) 11 (6.2) 1 (1.0) 1 (1.4) 2 (1.2) 10 (5.1) 3 (2.0) 13 (3.7)
Notes: *Statistically significant difference (p < 0.05) between prevalence among females vs males; aPrevalence of ulcerative STIs restricted to the n = 3 participants
who had a genital ulcer identified during physical exams, which was swabbed and tested using multiplex NAAT testing; bAs per the study inclusion criteria, all
participants reported being HIV-negative or unknown HIV status at enrollment
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[16, 30]. By providing immediate testing results and facili-
tating treatment without delay, POC tests can help reduce
secondary transmission and the consequences of infection
progression [31]. POC testing also presents an oppor-
tunity to screen outside of traditional clinic settings,
which young people infrequently access [32], and move
testing into community-based and youth-friendly set-
tings that offer comprehensive HIV and GTI services.
POC testing quality is growing with improving technol-
ogy [33], with good performance across several preva-
lent STIs, including CT, NG, TV, and syphilis [34, 35].
Recent work also suggests that POC testing for STIs is
acceptable to providers [33] and to young women and
their partners [16]. Additional studies are warranted to
assess the cost-effectiveness of POC STI testing for
youth in low- and middle-income countries.
GTI control will not be solved by diagnostic innovation
alone. In addition to GTI burden, and consistent with
previous studies [1], youth in our study report high be-
havioral, social, and structural vulnerability for GTI and
HIV acquisition. Notably, over half of adolescent and
young adults in this HIV hyper-endemic setting
self-perceived themselves as being at low or no risk of
HIV acquisition. These findings underscore the need
for efforts to move beyond individual-level risk factors
for promoting healthy sexuality for young people, and
address the social and structural risk environments,
such as gender and power inequity in relationships, co-
ercive sex, economic inequity, violence, and poverty,
which shape how young people navigate their sexual
lives.
This study has limitations. First, HSV-2 and syphilis
prevalence are likely to be under-estimated as the study
protocol specified NAAT testing of genital ulcerative le-
sions only. Future work should incorporate serological
testing to assess the true prevalence of both HSV-2 and
syphilis in youth. Second, not all GTIs were tested (for
example, anorectal samples were not taken), thus the
reported GTI prevalence may be an underestimate.
Third, participants were asked directly about GTI
symptoms and their genital areas carefully examined by
a study nurse with expertise in youth-focused care de-
livery, and may have been more willing to report symp-
toms or undergo genital examination. Thus, our
assessment of the sensitivity and PPV of syndromic
management of GTIs among youth, although very low,
Table 4 Sex-stratified sensitivity analyses of syndromic screening for genital tract infections (GTIs) among sexually experienced, non-
pregnant South African youth (aged 16–24 years) enrolled in the AYAZAZI study (n = 352)











Females (n = 198)
Vaginal discharge (VDS)a Yes 19 2 21 13.7 96.6 90.5 32.2
No 120 57 177 [8.4–20.5] [88.2–99.6] [69.6–98.8] [25.4–39.6]
with cervical STIs as causative agentsb Yes 7 14 21 11.7 89.9 33.3 70.1
No 53 124 177 [4.8–22.6] [83.6–94.3] [14.6–57.0] [62.7–76.7]
with vaginal STIs as causative agentsc Yes 18 3 21 14.8 96.1 85.7 41.2
No 104 73 177 [9.0–22.3] [88.9–99.2] [63.7–97.0] [33.9–48.9]
with only BV as a causative agent Yes 14 7 21 13.3 92.5 66.7 48.6
No 91 86 177 [7.5–21.4] [85.1–96.9] [43.0–85.4] [41.0–56.2]
Lower abdominal pain (LAP)d Yes 4 9 13 7.0 93.4 30.8 70.6
No 53 127 180 [1.9–17.0] [87.8–97.0] [9.1–61.4] [63.3–77.1]
Males (n = 154)
Male urethritis (MUS)e Yes 0 1 1 0.0 99.3 0.0 89.5
No 16 137 153 [0–20.6]g [96.0–100.0] [0–97.5]g [83.6–93.9]
Scrotal Swelling (SSW)f Yes 0 0 0 0.0 100.0 N/A 91.6
No 13 141 154 [0–24.7]g [97.4–100.0]g [N/A] [86.0–95.4]
Notes: GTIs included as the gold standard for VDS, LAP, MUS and SSW include (note: no sensitivity analysis was performed for GUD given testing via genital swabs
and NAAT:
aAny STI/GTI with VDS as a syndrome: N.gonorrhoeae, C.trachomatis, M.genitalium (cervical infection), T.vaginalis, BV, or C. albicans (vaginal infection);
bAny cervical STI with VDS as a syndrome: N.gonorrhoeae, C.trachomatis, M.genitalium;
cAny vaginal STI with VDS as a syndrome: T.vaginalis, BV, C. albicans;
dAny STI/GTI with LAP as a syndrome: N.gonorrhoeae, C.trachomatis, M.genitalium
eAny STI with MUS as syndrome: N.gonorrhoeae, C.trachomatis, M.genitalium, T.vaginalis;
fAny STI with SSW as syndrome: N.gonorrhoeae, C.trachomatis;
g1-sided 97.5% CI
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is likely higher than would be observed in a public care
setting.
Conclusion
Maintaining the status quo of syndromic GTI manage-
ment for youth is not acceptable. We observed a
substantial burden of subclinical GTI infection along-
side HIV risk behaviors and low risk-perception for
HIV acquisition among South African youth. Sensitivity
of symptom-based reporting was poor and offered no
value in identifying the highly prevalent asymptomatic
GTI infections. Syndromic management does not meet
the needs of young people in this and similar settings
and leaves them at increased risk of HIV acquisition. In
the context of evolving and less costly GTI diagnostic
capabilities, exploring new approaches to implementing
youth-focused GTI services is warranted.
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